Posted 19 May, 2021
IOVANCE BIOTHERAPEUTICS, INC. appointed Dr. Fardis as new CEO
Nasdaq:IOVA appointed new Chief Executive Officer Dr. Fardis in a 8-K filed on 19 May, 2021.
In the meantime, effective upon Dr. Fardis' departure, the Board of Directors of the Company will appoint Frederick G. Vogt, Ph.D., the Company's current General Counsel, as the Company's interim President and CEO.
Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of IOVANCE BIOTHERAPEUTICS, INC.
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Chief Executive Officer
On May 18, 2021, Maria Fardis, Ph.D., the Chief Executive Officer ("CEO") of Iovance Biotherapeutics, Inc. (the "Company"), notified the Company that she will be resigning as President, CEO and a director of the Company to pursue other opportunities. The Company will immediately begin a search for a successor. In the meantime, effective upon Dr. Fardis' departure, the Board of Directors of the Company will appoint Frederick G. Vogt, Ph.D., the Company's current General Counsel, as the Company's interim President and CEO.
1
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.